AU2010273261B2 - Tazarotene derivatives - Google Patents

Tazarotene derivatives Download PDF

Info

Publication number
AU2010273261B2
AU2010273261B2 AU2010273261A AU2010273261A AU2010273261B2 AU 2010273261 B2 AU2010273261 B2 AU 2010273261B2 AU 2010273261 A AU2010273261 A AU 2010273261A AU 2010273261 A AU2010273261 A AU 2010273261A AU 2010273261 B2 AU2010273261 B2 AU 2010273261B2
Authority
AU
Australia
Prior art keywords
ethynyl
optionally substituted
tazarotene
dimethylthiochroman
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010273261A
Other languages
English (en)
Other versions
AU2010273261A1 (en
Inventor
Michael J. Bishop
Xin Frank Cai
Wendy Huang Chern
Alan Colborn
Xue Ge
Hans Hofland
Hansen Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Laboratories Inc
Original Assignee
Stiefel Research Australia Pty Ltd
Stiefel Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Research Australia Pty Ltd, Stiefel Laboratories Inc filed Critical Stiefel Research Australia Pty Ltd
Publication of AU2010273261A1 publication Critical patent/AU2010273261A1/en
Application granted granted Critical
Publication of AU2010273261B2 publication Critical patent/AU2010273261B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010273261A 2009-07-16 2010-07-16 Tazarotene derivatives Ceased AU2010273261B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21379409P 2009-07-16 2009-07-16
US61/213,794 2009-07-16
US27225709P 2009-09-04 2009-09-04
US61/272,257 2009-09-04
PCT/US2010/042225 WO2011009023A1 (en) 2009-07-16 2010-07-16 Tazarotene derivatives

Publications (2)

Publication Number Publication Date
AU2010273261A1 AU2010273261A1 (en) 2012-02-02
AU2010273261B2 true AU2010273261B2 (en) 2013-07-25

Family

ID=43449815

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010273261A Ceased AU2010273261B2 (en) 2009-07-16 2010-07-16 Tazarotene derivatives

Country Status (16)

Country Link
US (3) US20120115909A1 (enExample)
EP (1) EP2453746A4 (enExample)
JP (1) JP5635090B2 (enExample)
KR (1) KR101536806B1 (enExample)
CN (1) CN102595892B (enExample)
AU (1) AU2010273261B2 (enExample)
BR (1) BR112012001680A2 (enExample)
CA (1) CA2768015C (enExample)
EA (1) EA022322B1 (enExample)
IL (1) IL217519A (enExample)
IN (1) IN2012DN00546A (enExample)
MX (1) MX2012000768A (enExample)
NZ (1) NZ598240A (enExample)
SG (1) SG177579A1 (enExample)
WO (1) WO2011009023A1 (enExample)
ZA (1) ZA201200253B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105050D0 (en) 2011-03-25 2011-05-11 Iiaa Ltd Pharmaceutical agent
CN111298120A (zh) * 2011-06-24 2020-06-19 格里生物公司 炎性病症的预防和治疗
CN106918676B (zh) * 2015-12-24 2020-08-11 重庆华邦制药有限公司 分离测定他扎罗汀倍他米松乳膏中两种药物含量及有关物质的方法
CN107176945B (zh) * 2016-03-11 2021-06-08 中国科学院上海有机化学研究所 一种视黄酸类化合物、其制备方法、中间体及应用
WO2017152725A1 (zh) * 2016-03-11 2017-09-14 中国科学院上海有机化学研究所 一种视黄酸类化合物、其制备方法、中间体及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017914A2 (en) * 2006-08-08 2008-02-14 Fernando Ahumada Ayala Topical antiacne preparations containing retinoid (tazarotene or adapalene), antibiotic (clindamycin phosphate) and/or keratolytic (miscrosponged benzoyl peroxide)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801593A (en) * 1979-09-13 1989-01-31 Burroughs Wellcome Co. Chemotherapeutic agents
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US4980369A (en) 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5399561A (en) * 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5183827A (en) * 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5045551A (en) 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
HUT63405A (en) 1990-10-09 1993-08-30 Allergan Inc Process for producing acetylene derivatives substituted with chromanyl, thiochromanyl or tetrahydroquinolinyl group and having retinoid-like activity, as well as pharmaceutical compositions comprising same as active ingredient
EP0571546B1 (en) 1991-02-13 1996-10-16 Allergan, Inc. Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity
EP0577737A1 (en) 1991-03-26 1994-01-12 Allergan, Inc. Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
AU9259598A (en) * 1997-07-08 1999-02-08 Gist-Brocades B.V. Topical application of a combination of benzoyl peroxide and a second active ingredient
AU5132799A (en) * 1998-07-28 2000-02-21 Bershad, Susan Short contact treatment of acne and photoaging with topical retinoids
US6048902A (en) * 1999-02-12 2000-04-11 Lebwohl; Mark G. Short contact treatment of psoriasis with topical retinoids
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
CN1210041C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
ITMI20050357A1 (it) * 2005-03-08 2006-09-09 Solmag S P A Procedimento di preparazione del tazarotene
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
EA200970724A1 (ru) * 2007-02-01 2010-02-26 Сол-Джел Текнолоджиз Лтд. Композиции для местного применения, содержащие пероксид и ретиноид

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017914A2 (en) * 2006-08-08 2008-02-14 Fernando Ahumada Ayala Topical antiacne preparations containing retinoid (tazarotene or adapalene), antibiotic (clindamycin phosphate) and/or keratolytic (miscrosponged benzoyl peroxide)

Also Published As

Publication number Publication date
IL217519A (en) 2015-06-30
IL217519A0 (en) 2012-02-29
CN102595892B (zh) 2014-09-10
US20140357669A1 (en) 2014-12-04
US20140357672A1 (en) 2014-12-04
KR20120056821A (ko) 2012-06-04
EP2453746A4 (en) 2013-04-24
SG177579A1 (en) 2012-02-28
US20120115909A1 (en) 2012-05-10
MX2012000768A (es) 2012-02-13
JP2012533564A (ja) 2012-12-27
AU2010273261A1 (en) 2012-02-02
CA2768015C (en) 2016-03-15
US9062037B2 (en) 2015-06-23
EA022322B1 (ru) 2015-12-30
CA2768015A1 (en) 2011-01-20
JP5635090B2 (ja) 2014-12-03
CN102595892A (zh) 2012-07-18
IN2012DN00546A (enExample) 2015-06-12
KR101536806B1 (ko) 2015-07-14
NZ598240A (en) 2013-10-25
BR112012001680A2 (pt) 2015-09-01
EP2453746A1 (en) 2012-05-23
ZA201200253B (en) 2013-05-29
EA201270176A1 (ru) 2012-08-30
WO2011009023A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
US10731159B2 (en) Cationic lipid
US9062037B2 (en) Tazarotene derivatives
EP3724194B1 (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
TWI360539B (en) 3-carbamoyl-2-pyridone derivatives
EP2040703B1 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
EP4011898B1 (en) 3-hydroxy-5-pregnane-20-one derivative and use thereof
FR2904316A1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
RU2753490C2 (ru) Модуляторы ror-гамма
CN118146236A (zh) 经取代的二氢噻吩并氮杂芳基衍生物及其前药的制备方法和用途
JP2022512652A (ja) Ｐ２ｘ３拮抗薬での皮膚掻痒症の治療
HK1199217A1 (en) Topical pharmaceutical composition including active agents
JP2023509441A (ja) トファシチニブおよびフィンゴリモドを含む局所組成物
EP4406537A1 (en) Long-chain compound and use thereof
JP3508042B2 (ja) セラミド合成促進剤
EP2794603B1 (en) [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors
JP6778362B2 (ja) グルタチオン産生促進剤
JP2016530289A (ja) 重水素化合物
AU2022330231B2 (en) Local topical formulation containing jak inhibitor or salt thereof or crystal form thereof, preparation method therefor and application thereof
Hu et al. Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production
WO2018022797A1 (en) Dermatological formulations of 2-(2-ethoxy-2-oxoethyl)(methyl)amino-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate
US9408793B2 (en) Selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositions
HK40041148B (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
JPWO2006059768A1 (ja) ９，１０−セコプレグナン誘導体及び医薬
HK40039957A (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
WO2004032914A2 (en) Use of a propargyl alcohol enantiomer for the treatment of dermatological disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired